Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
SalvaRx Group plc ("SalvaRx"), another portfolio investment, has also now completed its sale of 94.2% of SalvaRx Limited to Portage Biotech Inc. ("Portage") in exchange for new shares in Portage which are being distributed to SalvaRx shareholders and which are expected to be delivered shortly. Portage is listed on the CSE (Toronto) and NASDAQ (New York).
Got it
Will be interesting to see how it plays through
Anyone wiser like to comment
Take a look at the Balance Sheet of ABE - in the books at £565k at the half year
??????
Would we have benefited much from the disposal of its 94% interest and what is now likely to happen to our holding in the resulting shell company I wonder.
It’s relentless ??
Looking for a bit of a trade recovery this year
Update ?
A bit of buying pressure here and it would be great fun and games
There's only 2 Million shares. You're never getting heavy volume here!
Wonder if there may be news coming here? It is a pretty big move up, on light volume.
Not sure why they have got 24 employees for tiny £1.6m revenue here. Massively overstaffed. They could easily bin 10-15 of those workers and managers and instantly become very profitable overnight. With so few shares available, even the smallest tweaks to staff numbers would send the price through the roof.
I wonder if the forthcoming AGM will tell us how well we will do from the Salvarx deal. CW who has an interest in Salvrx has added shares and no doubt sees the potential here with tax losses and an improving trading environment.
Director buy.
So a good buy then!
400k mcap company with a £1.35m pension deficit? good luck with that.
Only a couple of days before the figures are announced and it willl be interesting to see if the improvement hinted at at the half way has continued. Low mc, not very liquid with only one mm and the business focused on the oil sector which is flying at the moment offshore Scotland, supported by assets of £2 per share and with substantial tax losses the sp could be ready to respond. A dull company perhaps but look beyond what you see as there much more to be had IMO
These are due by the end of the month and with the oil sector on the up there could be a positive update for the current year. Assets are worth about £2 so an RTO by an oil focussed company could be on the cards.
Freehold property in the books at nil - written down from nearly £700k with large tax losses!
(-25.00%)down
last nights close @40p was a rise of +33.33% on the previous days close. Noted 12Apr 2017.
?????
As a third generation shareholder, my inherited holding represented by a single share, added to by my own purchases, but insignificant after massive dilution and continuous failure to deliver, I wonder why this is still a public company? If all it does is make a living for staff and directors, why not take it private, as seemingly, no other company wishes to merge or purchase. A truly British story of failure over more than a century.
heads east, sniffs out an aluminium deal; http://www.investegate.co.uk/assoc-british-enging--asbe-/rns/annual-financial-report/201407080700086657L/ Extreme thumb twiddling from all-things-diesel ABSE. Head scratching stuff. GL out thar....
sleeper share finally crawls out of bed, then falls asleep on the floor. Small consolation is that the recent profit warning, and news of a puzzlingly inert Akoris, have hardly dented the shareprice; this is barnstorming stuff only in my dreams, a surefire cure for high blood pressure. Omens are middling, but bring on that annual Financial report, scheduled for the end of the month and let's see where we stand.....c'mon ASBE! GL if anyone out there, otherwise me, Billy no mates...
this is an asset heavyweight on the sly, plentiful moolah to pay debts if they wish. Also the Akoris investment may be an inspired move, what with a better year forecast for commodities/ natural resources. Hefty spread, but SO few shares issued...what a life! GL if any fellow holders out there, oh, and of course,DYOR, IMVVHO, etc.